Iomai Corp.

Dr. Douglas has served as a Director since January 2003. Dr. Douglas was President of Merck Vaccines, responsible for the research, development, manufacturing, and marketing of Merck s vaccine products until May 1999. He grew the vaccine business from $300 million to $1.2 billion, launched four new products, invested heavily in manufacturing facilities as well as research and development, and expanded the business globally. Prior to joining Merck in 1989, Dr. Douglas had a distinguished career as a physician and academician, specializing in infectious diseases. From 1982 to 1990, he was a Professor of Medicine and Chairman of the Department of Medicine at Cornell University Medical College and Physician in Chief of New York Hospital. He also served as Head of the Infectious Disease Unit at the University of Rochester School of Medicine. Dr. Douglas currently acts as consultant to the Vaccine Research Center at the National Institute of Health and serves on the boards of directors of several biotech companies and non-profits interested in vaccines and world health. Dr. Douglas is a graduate of Princeton University and Cornell University Medical College. He received his medical staff training at New York Hospital and Johns Hopkins Hospital.

Dr. Glenn pioneered the use of the skin immune system for the purposes of immunization and with his team has developed passive vaccine delivery systems such as patches to provide effective, needle-free delivery. Dr. Glenn and his team have established the field of transcutaneous immunization (TCI) and lead its development through peer-review publications and scientific meetings. As a founder of Iomai, he has been responsible for the conception, implementation and development of the basic science and early clinical trials, and he has multiple patents, publications and book chapters describing TCI. Dr. Glenn was trained at the Walter Reed Army Institute of Research where he worked in basic and clinical research relating to adjuvants and vaccine delivery. He received his B.A. at Whitman College, M.D. at the ORU School of Medicine in Oklahoma, received a military HPSP scholarship, and completed his pediatric training at the Madigan Army Medical Center.

Mr. Wilson is responsible for overseeing Iomai's financial strategy, including external relations with both investment banks and tax and securities regulators. He also structures and negotiates business deals. Mr. Wilson joined Iomai in 2000 as Vice President, Business Development and was responsible for overseeing the development of Iomai's business relationships and commercialization of products and technologies. Mr. Wilson came to Iomai from North American Vaccine, Inc. (NAVA), which was sold to Baxter Healthcare in 2000. Mr. Wilson received a B.A. from Princeton University and holds a M.B.A./J.D. from the University of Virginia.

Dr. Chen is responsible for developing our business relationships and our intellectual property portfolio. Prior to Iomai, Dr. Chen was the Chief of the Cancer and Biological Modifiers Branch at the NIH's Office of Technology Transfer. He also worked at MedImmune, Inc. in various business development capacities with increasing responsibilities. He received a Ph.D. in Biophysics from the University of Illinois and an MBA in Technology Management/Marketing from UCLA.

Dr. Poffenberger joined Iomai as Vice President, Regulatory Affairs, in November 2005. She leads the regulatory strategy, submissions and compliance activities for all products. Dr. Poffenberger has over 18 years experience in the pharma/biotech field, including 10 years at the Food and Drug Administration. She has worked with authorities in the United States, Canada, the United Kingdon and the European Union and led successful submissions at investigational, market application and postmarket product stages. Most recently she served as senior director of regulatory affairs at MedImmune Inc., where she headed the vaccines regulatory group responsible for FluMist and all other vaccines. Dr. Poffenberger has also worked as a regulatory affairs director for Baxter BioSciences. Dr. Poffenberger holds a B.S. in Biochemistry from Carnegie-Mellon University and a Ph.D. in Microbiology from the University of Chicago.

Dr. Ellingsworth leads scientific efforts at Iomai with a focus on transcutaneous immunization. He has 25 years of experience in research management in the pharmaceutical and biotechnology industries, including at Collagen Corp., Celtrix Pharmaceuticals, and Antex Biologics. Dr. Ellingsworth received his B.S. in Genetics from the University of California-Davis (UCD), an M.S. in Genetics from California State University, and a Ph.D. in Immunology from UCD.

Dr. Seid has served as Vice President, Formulations since August 2005. Dr. Seid leads Iomai's formulation development and analytical methods groups to develop products for transcutaneous immunization. Prior to joining Iomai, Dr. Seid had over 20 years of experience in directing formulation optimization and characterization of biological products. He had previously served as senior director of formulations and process development at Wyeth Vaccines Research, and as director, formulation development at Aviron (now MedImmune Vaccine, Inc.). Dr. Seid earned his B.S. in Chemistry from the University of California-Berkeley and his Ph.D. in Chemistry from Boston University.

Dr. Frech directs the design and execution of Iomai's clinical programs. Prior to joining Iomai, Dr. Frech worked for Baxter Vaccines in Vienna, Austria and Baxter Vaccines in Columbia, Maryland. Dr. Frech holds a bachelor's degree from Dartmouth College, a D.V.M. from Washington State University and is a board-certified veterinarian. She has also an M.P.H. from Johns Hopkins University Bloomberg School of Public Health.

M. James Barrett, Ph.D. has served as a general partner of NEA Partners 10 Limited Partnership, the general partner of New Enterprise Associates 10 Limited Partnership, a venture capital fund, since August 2001. From January 1997 to August 2001, he served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, Inc., a medical device company, which he founded in 1997. He continues to serve as the Chairman of its Board of Directors. Dr. Barrett also serves on the Boards of Directors of two publicly-held biopharmaceutical companies: Taragacept, Inc. and YM Biosciences, Inc., and the Boards of several privatelyheld biopharmaceutical companies. Dr. Barrett received a B.S. in Chemistry from Boston College, a Ph.D. in Biochemistry from the University of Tennessee and a M.B.A. from the University of Santa Clara.